These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 36747186

  • 1. Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction.
    Trombara F, Cosentino N, Bonomi A, Ludergnani M, Poggio P, Gionti L, Baviera M, Colacioppo P, Roncaglioni MC, Leoni O, Bortolan F, Agostoni P, Genovese S, Marenzi G.
    Cardiovasc Diabetol; 2023 Feb 06; 22(1):26. PubMed ID: 36747186
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes.
    Marfella R, Prattichizzo F, Sardu C, Rambaldi PF, Fumagalli C, Marfella LV, La Grotta R, Frigé C, Pellegrini V, D'Andrea D, Cesaro A, Calabrò P, Pizzi C, Antonicelli R, Ceriello A, Mauro C, Paolisso G.
    Cardiovasc Diabetol; 2024 Jan 06; 23(1):10. PubMed ID: 38184582
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I, Pavlidis G, Thymis J, Birba D, Kalogeris A, Kousathana F, Kountouri A, Balampanis K, Parissis J, Andreadou I, Katogiannis K, Dimitriadis G, Bamias A, Iliodromitis E, Lambadiari V.
    J Am Heart Assoc; 2020 May 05; 9(9):e015716. PubMed ID: 32326806
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes.
    Nørgaard CH, Starkopf L, Gerds TA, Vestergaard P, Bonde AN, Fosbøl E, Køber L, Wong ND, Torp-Pedersen C, Lee CJ.
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep 03; 8(6):549-556. PubMed ID: 34215881
    [Abstract] [Full Text] [Related]

  • 8. Sodium-glucose co-transporter-2 inhibitors and the risk of venous thromboembolism: A nationwide population-based study and meta-analysis.
    Tsai HR, Lin YJ, Yeh JI, Huang YC, Liu PP, Peng CC, Hsu JY, Lee YC, Loh CH, Lin SM, Huang HK.
    Diabetes Metab Res Rev; 2024 Feb 03; 40(2):e3739. PubMed ID: 37862117
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    Kintzoglanakis K, Diamantis C, Mariolis A, Paschou SA.
    Diab Vasc Dis Res; 2024 Feb 03; 21(4):14791641241269743. PubMed ID: 39139128
    [Abstract] [Full Text] [Related]

  • 11. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, Tunnicliffe D, Ruospo M, Natale P, Saglimbene V, Nicolucci A, Johnson DW, Tonelli M, Rossi MC, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque LI, Lloyd A, Ahmad N, Liu Y, Tiv S, Millard T, Gagliardi L, Kolanu N, Barmanray RD, McMorrow R, Raygoza Cortez AK, White H, Chen X, Zhou X, Liu J, Rodríguez AF, González-Colmenero AD, Wang Y, Li L, Sutanto S, Solis RC, Díaz González-Colmenero F, Rodriguez-Gutierrez R, Walsh M, Guyatt G, Strippoli GFM.
    BMJ; 2021 Jan 13; 372():m4573. PubMed ID: 33441402
    [Abstract] [Full Text] [Related]

  • 12. Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.
    Sohn M, Dietrich JW, Nauck MA, Lim S.
    Cardiovasc Diabetol; 2023 Jun 28; 22(1):153. PubMed ID: 37381019
    [Abstract] [Full Text] [Related]

  • 13. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
    D'Andrea E, Kesselheim AS, Franklin JM, Jung EH, Hey SP, Patorno E.
    Cardiovasc Diabetol; 2020 Sep 29; 19(1):154. PubMed ID: 32993654
    [Abstract] [Full Text] [Related]

  • 14. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.
    Fu EL, Mastrorilli J, Bykov K, Wexler DJ, Cervone A, Lin KJ, Patorno E, Paik JM.
    Kidney Int; 2024 Mar 29; 105(3):618-628. PubMed ID: 38101515
    [Abstract] [Full Text] [Related]

  • 15. Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status.
    Bea S, Jeong HE, Filion KB, Yu OH, Cho YM, Lee BH, Chang Y, Byrne CD, Shin JY.
    JAMA Netw Open; 2023 Dec 01; 6(12):e2349856. PubMed ID: 38153732
    [Abstract] [Full Text] [Related]

  • 16. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D, Christiansen MN, Mogensen UM, Bundgaard JS, Rørth R, Madelaire C, Fosbøl EL, Schou M, Torp-Pedersen C, Gislason G, Køber L, Kristensen SL.
    Cardiovasc Diabetol; 2020 Jul 06; 19(1):107. PubMed ID: 32631337
    [Abstract] [Full Text] [Related]

  • 17. Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom.
    Brunetti VC, St-Jean A, Dell'Aniello S, Fisher A, Yu OHY, Bugden SC, Daigle JM, Hu N, Alessi-Severini S, Shah BR, Ronksley PE, Lix LM, Ernst P, Filion KB, Canadian Network for Observational Drug Effect Studies (CNODES) Investigators.
    BMC Endocr Disord; 2022 Sep 29; 22(1):241. PubMed ID: 36175881
    [Abstract] [Full Text] [Related]

  • 18. Microglia Involvement into Acute and Chronic Brain Damage in Diabetic Rats: Impact of GLP-1RA and SGLT-2i.
    Simanenkova A, Fuks O, Timkina N, Islamova A, Sufieva D, Kirik О, Korzhevskii D, Vlasov T, Karonova T.
    Front Biosci (Landmark Ed); 2024 Jul 24; 29(7):265. PubMed ID: 39082364
    [Abstract] [Full Text] [Related]

  • 19. Pharmacist impact on evidence-based prescribing of diabetes medications in patients with clinical atherosclerotic cardiovascular disease.
    Trueman C, Shin E, Donovan A, McAdam-Marx C, Coan C.
    J Manag Care Spec Pharm; 2023 Dec 24; 29(12):1275-1283. PubMed ID: 38058135
    [Abstract] [Full Text] [Related]

  • 20. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
    Zhang Y, Jiang L, Wang J, Wang T, Chien C, Huang W, Fu X, Xiao Y, Fu Q, Wang S, Zhao J.
    Cardiovasc Diabetol; 2022 Nov 05; 21(1):232. PubMed ID: 36335326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.